Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) EBITDA Margin (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of EBITDA Margin readings, the most recent being 0.06% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 173.0% to 0.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 19.43%, a 886.0% decrease, with the full-year FY2025 number at 19.43%, down 886.0% from a year prior.
  • EBITDA Margin hit 0.06% in Q4 2025 for Tandem Diabetes Care, up from 7.92% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 4.85% in Q4 2021 to a low of 72.11% in Q1 2023.
  • Median EBITDA Margin over the past 5 years was 8.94% (2022), compared with a mean of 14.68%.
  • Biggest five-year swings in EBITDA Margin: tumbled -6236bps in 2023 and later soared 4863bps in 2024.
  • Tandem Diabetes Care's EBITDA Margin stood at 4.85% in 2021, then tumbled by -218bps to 5.72% in 2022, then tumbled by -135bps to 13.43% in 2023, then surged by 87bps to 1.79% in 2024, then skyrocketed by 97bps to 0.06% in 2025.
  • The last three reported values for EBITDA Margin were 0.06% (Q4 2025), 7.92% (Q3 2025), and 20.25% (Q2 2025) per Business Quant data.